Management of DVT Following Hip Bruise
A DVT that develops after a hip bruise should be managed with therapeutic anticoagulation using a direct oral anticoagulant (DOAC) as first-line therapy—specifically apixaban or rivaroxaban—for a minimum of 3 months, as this represents a provoked DVT with a transient risk factor (trauma). 1
Initial Diagnostic Confirmation
Before initiating treatment, confirm the DVT diagnosis using:
- Clinical probability assessment (Wells score for DVT)
- D-dimer testing if DVT is "unlikely" by clinical assessment
- Compression ultrasonography as definitive imaging 2
If clinical probability is "DVT likely," proceed directly to compression ultrasound without D-dimer testing 2.
Anticoagulation Selection and Dosing
Preferred first-line therapy: Direct oral anticoagulants (DOACs) over vitamin K antagonists 1
Specific DOAC Regimens (FDA-approved):
Rivaroxaban: 15 mg twice daily for 21 days, then 20 mg once daily 2
Apixaban or edoxaban are equally acceptable alternatives 1
Key advantage: DOACs can be initiated immediately without requiring parenteral bridging therapy (unlike dabigatran or edoxaban which require 5-10 days of parenteral anticoagulation first) 1, 2
Alternative if DOACs contraindicated:
Low-molecular-weight heparin (LMWH) preferred over unfractionated heparin 2, 3
- Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 2
- Dalteparin: 200 U/kg subcutaneously once daily 2
If bridging to warfarin, overlap LMWH for minimum 5 days AND until INR ≥2.0 for at least 24 hours (target INR 2.0-3.0) 1, 2
Duration of Anticoagulation
For this provoked DVT (trauma from hip bruise): 3 months of therapeutic anticoagulation is sufficient 1, 3
The guideline explicitly states: "In patients with VTE diagnosed in the setting of a major transient risk factor, we recommend against offering extended-phase anticoagulation" 1. Trauma qualifies as a transient risk factor.
Do NOT extend beyond 3-6 months unless the patient develops recurrent VTE 1, 3
Outpatient vs Inpatient Management
Outpatient treatment is preferred if the following criteria are met 1:
- Adequate home circumstances
- Access to medications and outpatient care
- No hemodynamic instability
- No concomitant pulmonary embolism requiring hospitalization
Most patients with isolated lower extremity DVT can be safely managed as outpatients 1, 3.
Adjunctive Measures
Early ambulation is recommended over bed rest 1
Compression stockings: While previously recommended, the most recent 2024 CHEST guidelines did not provide a strong recommendation for routine use to prevent post-thrombotic syndrome 1. This represents evolving evidence in this area.
Critical Monitoring Considerations
For LMWH:
- Monitor platelet count every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients on unfractionated heparin 2, 4
- Caution with renal impairment: LMWH accumulates if CrCl <30 mL/min; fondaparinux is contraindicated 2
For DOACs:
- Dose adjustment may be needed with renal dysfunction
- Avoid in pregnancy 2
Common Pitfalls to Avoid
- Do not use vitamin K antagonists as monotherapy initially—they require parenteral bridging 1
- Do not extend anticoagulation beyond 3-6 months for this provoked DVT—the trauma (hip bruise) is a transient risk factor 1, 3
- Do not routinely place IVC filters—these are reserved for contraindications to anticoagulation 4
- Do not delay ambulation—early mobilization is safe and recommended 1
Special Consideration: Cancer Screening
While not explicitly required for trauma-provoked DVT, if the patient has other risk factors or the "hip bruise" circumstances are unclear, consider whether this represents truly isolated trauma or if underlying malignancy could be contributing. However, for a clearly trauma-related DVT, extensive cancer screening is not indicated.